Maryland Stem Cell Research Fund | ISSCR 2022 Focus Session

Описание к видео Maryland Stem Cell Research Fund | ISSCR 2022 Focus Session

Accelerating Cures - Translating Stem Cell Discoveries into Therapies
Organized by Maryland Stem Cell Research Fund (MSCRF)*

In this Focus session, join leaders in the field from Maryland, USA to explore the latest breakthroughs and advances in stem cell disease modeling and tissue engineering approaches. Also learn the key considerations to commercialize your discoveries, including insights on manufacturing and progressing to clinical trials. The topics will cover cutting-edge discoveries in cardiovascular, neurological and retinal disease as well as cell therapies for skin, bone and soft-tissue restoration. We will also hear how these ideas were validated and commercialized. The cell-based technologies discussed include ES, iPS, MSCs and fibroblast-based approaches. Hear from experts on creating, manufacturing and delivering cell therapies to patients with unmet medical needs.

Virtual Session Moderators:

Curt Civin, University of Maryland, School of Medicine, USA, Session Chair

Amritha Jaishankar, Maryland Stem Cell Research Fund, USA, Session Chair

Welcome and Overview:

Stuart Martin, University of Maryland, School of Medicine, USA
Microfluidic cell tethering (TetherChip) to improve analysis of stem cell sphere formation

Muhammad Mohiuddin, University of Maryland, School of Medicine, USA
First Pig to Human Cardiac Xenotransplantation: How We Got Here

Valina Dawson, Johns Hopkins University, School of Medicine, USA
Leveraging Human Brain Culture to Identify Therapeutic Targets

Panel Accelerating Cures- Translating stem cell discoveries into therapies
Jon Rowley, RoosterBio, USA
Doug Falk, Vita Therapeutics, USA
Sashank Reddy, LifeSprout, USA
Murat Kalayoglu, Cartesian Therapeutics, USA
Kapil Bharti, National Institutes of Health, USA

Learn more about MSCRF at ISSCR: https://www.isscr.org/meetings-events...

Learn more about MSCRF: https://www.mscrf.org/

Комментарии

Информация по комментариям в разработке